Document is current
Any future updates will be listed below
-
Authors
Rudwaleit, Martin https://orcid.org/0000-0001-5445-548X
Mørup, Michael F
Humphries, Brittany
Zannat, Noor-E
Willems, Damon
Taieb, Vanessa
Boonen, Annelies https://orcid.org/0000-0003-0682-9533
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00939003 at ClinicalTrials.govnct02696785 at ClinicalTrials.govDocuments that mention this clinical trial
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
https://doi.org/10.1136/annrheumdis-2012-201766
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
nct01114880 at ClinicalTrials.govDocuments that mention this clinical trial
POS0918 EVALUATION OF SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING IXEKIZUMAB THERAPY OVER 2 YEARS
https://doi.org/10.1136/annrheumdis-2021-eular.1620
Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials
https://doi.org/10.1007/s40744-025-00810-5
THU0396 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS FROM THE COAST-V AND COAST-W TRIALS AT 52 WEEKS
https://doi.org/10.1136/annrheumdis-2020-eular.2053
AB0710 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH AS MEASURED BY SF-36 IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS NAIVE TO BIOLOGICAL THERAPY: 52 WEEK RESULTS OF A PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2019-eular.1612
OP0046 EFFECT OF IXEKIZUMAB TREATMENT ON MRI STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS; A POST-HOC ANALYSIS OF A PLACEBO AND ACTIVE CONTROLLED RCT
https://doi.org/10.1136/annrheumdis-2024-eular.602
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (Results)
https://doi.org/10.1136/annrheumdis-2019-216118
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
OP0238 WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND TREATED WITH IXEKIZUMAB FOR 16 WEEKS: RESULTS FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1613
FRI0398 IXEKIZUMAB IS EFFECTIVE IN THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS REGARDLESS OF THE LEVEL OF C-REACTIVE PROTEIN OR MAGNETIC RESONANCE IMAGING SCORES: 16-WEEK DATA FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1466
FRI0420 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: SF-36 RESULTS OF TWO PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.1237
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
https://doi.org/10.1136/annrheumdis-2020-219717
POS0901 IXEKIZUMAB SHOWS A DISTINCT PATTERN OF PAIN IMPROVEMENT BEYOND INFLAMMATION IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.211
Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2021-001839
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
https://doi.org/10.1136/rmdopen-2021-002165
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
https://doi.org/10.1136/annrheumdis-2023-eular.82
FRI0400 LONG-TERM SAFETY OF IXEKIZUMAB IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS/ANKYLOSING SPONDYLITIS: AN INTEGRATED ANALYSIS OF COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1232
POS0909 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS AND QUALITY OF LIFE OF ANKYLOSING SPONDYLITIS IN PATIENTS IRRESPECTIVE OF HLA-B27 STATUS: POOLED RESULTS FROM THE COAST-V AND COAST-W TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.801
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
https://doi.org/10.1007/s12325-022-02132-2
POS0931 EFFICACY AND IMPROVEMENT IN PATIENT-REPORTED OUTCOMES AT WEEKS 16 AND 52 IN IXEKIZUMAB TREATED BIOLOGICAL NAÏVE PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS ACHIEVING CLINICALLY IMPORTANT PAIN AT NIGHT REDUCTION AT WEEK 16: RESULTS FROM COAST-V TRIAL
https://doi.org/10.1136/annrheumdis-2022-eular.169
POS0908 EFFICACY OF IXEKIZUMAB THROUGH 52 WEEKS FOR IMPROVING PERIPHERAL JOINT INVOLVEMENT AMONG PATIENTS WITH RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.761
POS0957 EXTERNAL VALIDATION OF THE ALTERNATIVE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN THREE PHASE-3 RCTs
https://doi.org/10.1136/annrheumdis-2022-eular.372
POS0915 SUSTAINABILITY OF IXEKIZUMAB RESPONSE AT THE INDIVIDUAL PATIENT LEVEL OVER TIME IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1340
OP0034 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS, AND QUALITY OF LIFE IN PATIENTS WITH AXIAL SpA IRRESPECTIVE OF DISEASE DURATION: RESULTS FROM THE COAST-V, COAST-W AND COAST-X TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.164
AB0868 HOW DO EARLY DISEASE ACTIVITY AND EARLY CLINICAL RESPONSE ASSOCIATE WITH LONG-TERM OUTCOMES WITH IXEKIZUMAB IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS?
https://doi.org/10.1136/annrheumdis-2024-eular.623
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration
https://doi.org/10.1007/s12325-025-03305-5
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
FRI0421 IXEKIZUMAB SIGNIFICANTLY REDUCED PAIN, INFLAMMATION, AND FATIGUE IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLARTHRITIS (R-AXSPA)/ANKYLOSING SPONDYLITIS (AS)
https://doi.org/10.1136/annrheumdis-2019-eular.1236
Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2024-004429
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
https://doi.org/10.1136/ard-2022-222731
nct01258738 at ClinicalTrials.govDocuments that mention this clinical trial
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial
https://doi.org/10.1136/annrheumdis-2012-202533
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
nct02696798 at ClinicalTrials.govDocuments that mention this clinical trial
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis
https://doi.org/10.1136/annrheumdis-2017-212008
THU0353 Change in mri structural lesions in the sacroiliac joint after two years of etanercept therapy in comparison to a contemporary control cohort in non-radiographic axial spondyloarthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1864
THU0382 Change in sacroiliac joint structural radiographic damage after two years of etanercept therapy in comparison to a contemporary control cohort in non-radiographic axial spondyloarthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1860
FRI0216 Detection of structural lesions on t1 weighted mri versus radiography of the si joints in early axial spondyloarthritis: 2-year data
https://doi.org/10.1136/annrheumdis-2018-eular.2124
OP0107 ETANERCEPT WITHDRAWAL AND RE-TREATMENT IN PATIENTS WITH INACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AT 24 WEEKS: RESULTS OF RE-EMBARK, AN OPEN-LABEL, PHASE IV TRIAL
https://doi.org/10.1136/annrheumdis-2020-eular.1322
OP0199 Sustained remission of inflammation is associated with reduced structural damage on sacroiliac joint magnetic resonance imaging in patients with early axial spondyloarthritis: evidence to support the concept of treat-to-target
https://doi.org/10.1136/annrheumdis-2018-eular.1114
Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis
https://doi.org/10.1136/annrheumdis-2017-211605
THU0375 Characteristics associated with improvements in SPARCC SIJ and asdas scores in patients with non-radiographic axial spondyloarthritis treated with etanercept
https://doi.org/10.1136/annrheumdis-2017-eular.1873
FRI0474 Does axial spondyloarthritis phenotype correlate with imaging morphotype?
https://doi.org/10.1136/annrheumdis-2017-eular.3681
Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study
https://doi.org/10.1136/annrheumdis-2017-211313
nct02757352 at ClinicalTrials.govDocuments that mention this clinical trial
POS0926 NORMALIZATION OF HIGH SENSITIVITY CRP VERSUS CLINICAL RESPONSE TO IXEKIZUMAB AT WEEK 16 IN PATIENTS WITH RADIOGRAPHIC & NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE COAST STUDIES
https://doi.org/10.1136/annrheumdis-2021-eular.2079
POS0918 EVALUATION OF SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING IXEKIZUMAB THERAPY OVER 2 YEARS
https://doi.org/10.1136/annrheumdis-2021-eular.1620
Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials
https://doi.org/10.1007/s40744-025-00810-5
THU0396 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS FROM THE COAST-V AND COAST-W TRIALS AT 52 WEEKS
https://doi.org/10.1136/annrheumdis-2020-eular.2053
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (Results)
https://doi.org/10.1136/annrheumdis-2019-216118
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
AB1321 PSYCHOMETRIC PROPERTIES OF THE ASAS HEALTH INDEX IN PATIENTS WITH ACTIVE AS/RADIOGRAPHIC AXIAL SPA WHO HAVE PRIOR INADEQUATE RESPONSE/INTOLERANCE TO TNF INHIBITORS IN A PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2019-eular.1615
OP0238 WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND TREATED WITH IXEKIZUMAB FOR 16 WEEKS: RESULTS FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1613
FRI0398 IXEKIZUMAB IS EFFECTIVE IN THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS REGARDLESS OF THE LEVEL OF C-REACTIVE PROTEIN OR MAGNETIC RESONANCE IMAGING SCORES: 16-WEEK DATA FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1466
FRI0420 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: SF-36 RESULTS OF TWO PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.1237
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
https://doi.org/10.1136/annrheumdis-2020-219717
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
https://doi.org/10.1136/rmdopen-2021-002165
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
https://doi.org/10.1136/annrheumdis-2023-eular.82
FRI0400 LONG-TERM SAFETY OF IXEKIZUMAB IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS/ANKYLOSING SPONDYLITIS: AN INTEGRATED ANALYSIS OF COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1232
POS0909 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS AND QUALITY OF LIFE OF ANKYLOSING SPONDYLITIS IN PATIENTS IRRESPECTIVE OF HLA-B27 STATUS: POOLED RESULTS FROM THE COAST-V AND COAST-W TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.801
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
https://doi.org/10.1007/s12325-022-02132-2
POS0908 EFFICACY OF IXEKIZUMAB THROUGH 52 WEEKS FOR IMPROVING PERIPHERAL JOINT INVOLVEMENT AMONG PATIENTS WITH RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.761
POS0957 EXTERNAL VALIDATION OF THE ALTERNATIVE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN THREE PHASE-3 RCTs
https://doi.org/10.1136/annrheumdis-2022-eular.372
POS0915 SUSTAINABILITY OF IXEKIZUMAB RESPONSE AT THE INDIVIDUAL PATIENT LEVEL OVER TIME IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1340
OP0034 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS, AND QUALITY OF LIFE IN PATIENTS WITH AXIAL SpA IRRESPECTIVE OF DISEASE DURATION: RESULTS FROM THE COAST-V, COAST-W AND COAST-X TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.164
AB0471 PATIENTS WITH RADIOGRAPHIC axSpA WHO PROGRESSED FROM ASAS20 AT WEEK 16 TO ASAS40 AT WEEK 52: RESULTS FROM COAST-W
https://doi.org/10.1136/annrheumdis-2021-eular.1823
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration
https://doi.org/10.1007/s12325-025-03305-5
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
FRI0421 IXEKIZUMAB SIGNIFICANTLY REDUCED PAIN, INFLAMMATION, AND FATIGUE IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLARTHRITIS (R-AXSPA)/ANKYLOSING SPONDYLITIS (AS)
https://doi.org/10.1136/annrheumdis-2019-eular.1236
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
https://doi.org/10.1136/ard-2022-222731
nct01358175 at ClinicalTrials.govDocuments that mention this clinical trial
POS0926 NORMALIZATION OF HIGH SENSITIVITY CRP VERSUS CLINICAL RESPONSE TO IXEKIZUMAB AT WEEK 16 IN PATIENTS WITH RADIOGRAPHIC & NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE COAST STUDIES
https://doi.org/10.1136/annrheumdis-2021-eular.2079
THU0395 EFFICACY OF IXEKIZUMAB ON DISEASE ACTIVITY AND QUALITY OF LIFE IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND OBJECTIVE SIGNS OF INFLAMMATION, STRATIFIED BY BASELINE CRP/SACROILIAC JOINT MRI STATUS
https://doi.org/10.1136/annrheumdis-2020-eular.2027
THU0384 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS PATIENTS: RESULTS FROM THE COAST-X TRIAL AT 52 WEEKS
https://doi.org/10.1136/annrheumdis-2020-eular.2056
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
https://doi.org/10.1136/annrheumdis-2020-219717
Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2021-001839
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
https://doi.org/10.1136/rmdopen-2021-002165
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
https://doi.org/10.1136/annrheumdis-2023-eular.82
FRI0278 IXEKIZUMAB IMPROVES SELF-REPORTED OVERALL FUNCTIONING AND HEALTH AS MEASURED BY THE ASAS HEALTH INDEX IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS OF A PHASE 3 RANDOMIZED, ACTIVE AND PLACEBO-CONTROLLED TRIAL (COAST-X)
https://doi.org/10.1136/annrheumdis-2020-eular.1361
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
https://doi.org/10.1007/s12325-022-02132-2
POS0957 EXTERNAL VALIDATION OF THE ALTERNATIVE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN THREE PHASE-3 RCTs
https://doi.org/10.1136/annrheumdis-2022-eular.372
OP0034 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS, AND QUALITY OF LIFE IN PATIENTS WITH AXIAL SpA IRRESPECTIVE OF DISEASE DURATION: RESULTS FROM THE COAST-V, COAST-W AND COAST-X TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.164
POS0301 STRUCTURAL OUTCOMES IN THE SACROILIAC JOINT AFTER IXEKIZUMAB TREATMENT FOR 16 WEEKS IN PATIENTS WITH ACTIVE NON‑RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY GENDER, HLA-B27, AND BASELINE MRI INFLAMMATION
https://doi.org/10.1136/annrheumdis-2022-eular.2322
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration
https://doi.org/10.1007/s12325-025-03305-5
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
https://doi.org/10.1136/ard-2022-222731
nct03928704 at ClinicalTrials.govDocuments that mention this clinical trial
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
https://doi.org/10.1136/annrheumdis-2016-210023
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
https://doi.org/10.1007/s40744-020-00269-6
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
https://doi.org/10.1007/s40744-021-00380-2
SAT0315 STRUCTURAL DAMAGE PROGRESSION OVER 4 YEARS OF SECUKINUMAB TREATMENT IN ANKYLOSING SPONDYLITIS: POST-HOC ANALYSIS OF MEASURE-1 TRIAL USING A LONGITUDINAL BAYESIAN MIXTURE MODEL
https://doi.org/10.1136/annrheumdis-2019-eular.4534
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
https://doi.org/10.1136/annrheumdis-2016-209730
FRI0271 IMPACT OF HLA-B27 STATUS ON CLINICAL OUTCOMES AMONG PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.1448
SAT0259 Low rate of spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison
https://doi.org/10.1136/annrheumdis-2018-eular.1899
THU0359 Secukinumab demonstrates consistent safety over long-term exposure (up to 3 years) in patients with active ankylosing spondylitis: pooled analysis of three phase 3 trials
https://doi.org/10.1136/annrheumdis-2017-eular.4894
THU0397 SYMPTOMS OF PERIPHERAL ARTHRITIS ARE SIGNIFICANTLY IMPROVED IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2217
SAT0270 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis
https://doi.org/10.1136/annrheumdis-2018-eular.4474
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
https://doi.org/10.1136/rmdopen-2018-000749
Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate
https://doi.org/10.1136/bmjopen-2020-039059
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
https://doi.org/10.1136/rmdopen-2019-001005
nct03928743 at ClinicalTrials.govDocuments that mention this clinical trial
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2025-005969
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2025-006174
POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.833
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
https://doi.org/10.1136/ard-2022-223595
AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.2758
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2024-004202
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
https://doi.org/10.1136/ard-2023-224803
POS1107 BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.836
POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.2416
POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2292
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2020-216980
POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.1996
POS0805 SUSTAINED IMPROVEMENTS WITH BIMEKIZUMAB IN PATIENT-REPORTED SYMPTOMS OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2197
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
https://doi.org/10.1136/rmdopen-2023-004040
POS0247 RESOLUTION OF ENTHESITIS AND PERIPHERAL ARTHRITIS WITH BIMEKIZUMAB IN PATIENTS WITH AXIAL SPODYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.831
POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.1562
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2024-005026
POS0246 BIMEKIZUMAB REDUCED MRI INFLAMMATORY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.786
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
https://doi.org/10.1136/ard-2024-225933
AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.760
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.1702
POS0058 IMPACT OF BIMEKIZUMAB ON MRI INFLAMMATORY AND STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS AND POST HOC ANALYSES FROM THE BE MOBILE 1 AND 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.4903
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2025-006013
nct01786668 at ClinicalTrials.govDocuments that mention this clinical trial
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2025-005969
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2025-006174
POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.833
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
https://doi.org/10.1136/ard-2022-223595
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2024-004202
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
https://doi.org/10.1136/ard-2023-224803
POS1107 BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.836
POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2292
LBA0003 MINIMAL SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS OVER 2 YEARS OF BIMEKIZUMAB TREATMENT: RESULTS FROM A PHASE 3 OPEN-LABEL EXTENSION STUDY
https://doi.org/10.1136/annrheumdis-2024-eular.lba62
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2020-216980
POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.1996
POS0805 SUSTAINED IMPROVEMENTS WITH BIMEKIZUMAB IN PATIENT-REPORTED SYMPTOMS OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2197
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
https://doi.org/10.1136/rmdopen-2023-004040
POS0247 RESOLUTION OF ENTHESITIS AND PERIPHERAL ARTHRITIS WITH BIMEKIZUMAB IN PATIENTS WITH AXIAL SPODYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.831
POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.1562
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2024-005026
OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.2441
POS0246 BIMEKIZUMAB REDUCED MRI INFLAMMATORY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.786
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
https://doi.org/10.1136/ard-2024-225933
AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.760
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.1702
Axial spondyloarthritis: new advances in diagnosis and management
https://doi.org/10.1136/bmj.m4447
POS0058 IMPACT OF BIMEKIZUMAB ON MRI INFLAMMATORY AND STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS AND POST HOC ANALYSES FROM THE BE MOBILE 1 AND 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.4903
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2025-006013
nct03502616 at ClinicalTrials.govDocuments that mention this clinical trial
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
AB0750 Back pain and morning stiffness as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
https://doi.org/10.1136/annrheumdis-2022-eular.28
OP0239 PSYCHOMETRIC EVALUATION OF FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS
https://doi.org/10.1136/annrheumdis-2021-eular.62
POS0296 INTEGRATED SAFETY ANALYSIS OF TOFACITINIB IN ANKYLOSING SPONDYLITIS CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.2076
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2019-001042
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
https://doi.org/10.1136/annrheumdis-2020-219601
Old and new treatment targets in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2015-000054
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2016-210322
THU0352 Tofacitinib treatment is associated with attainment of the minimally important reduction in axial mri inflammation in patients with ankylosing spondylitis
https://doi.org/10.1136/annrheumdis-2017-eular.2447
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial
https://doi.org/10.1136/rmdopen-2022-002253
SAT0221 Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/annrheumdis-2018-eular.3247
Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial
https://doi.org/10.1007/s40744-023-00564-y
AB0937 TOFACITINIB EFFICACY AND SAFETY IN PATIENTS WITH ANKYLOSING SPONDYLITIS BY BASELINE C‑REACTIVE PROTEIN LEVELS: A POST HOC ANALYSIS
https://doi.org/10.1136/annrheumdis-2023-eular.2118
nct00939003 at ClinicalTrials.govDocuments that mention this clinical trial
POS1116 TIME TO IMPROVEMENT OF PAIN, MORNING STIFFNESS AND DISEASE ACTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH TOFACITINIB
https://doi.org/10.1136/annrheumdis-2023-eular.2417
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
AB0750 Back pain and morning stiffness as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
https://doi.org/10.1136/annrheumdis-2022-eular.28
OP0239 PSYCHOMETRIC EVALUATION OF FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS
https://doi.org/10.1136/annrheumdis-2021-eular.62
POS0296 INTEGRATED SAFETY ANALYSIS OF TOFACITINIB IN ANKYLOSING SPONDYLITIS CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.2076
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
https://doi.org/10.1136/annrheumdis-2020-219601
POS0305 TIME TO IMPROVEMENT OF FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN A STUDY OF TOFACITINIB
https://doi.org/10.1136/annrheumdis-2022-eular.2391
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
https://doi.org/10.1136/ard-2023-223850
Improvement of Fatigue in Patients with Ankylosing Spondylitis Receiving Tofacitinib: Analyses of a Phase 3 Randomized Controlled Trial
https://doi.org/10.1007/s40744-024-00727-5
POS0895 EFFECT OF TOFACITINIB ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.106
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial
https://doi.org/10.1136/rmdopen-2022-002253
AB0937 TOFACITINIB EFFICACY AND SAFETY IN PATIENTS WITH ANKYLOSING SPONDYLITIS BY BASELINE C‑REACTIVE PROTEIN LEVELS: A POST HOC ANALYSIS
https://doi.org/10.1136/annrheumdis-2023-eular.2118
nct02696785 at ClinicalTrials.govDocuments that mention this clinical trial
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
https://doi.org/10.1136/annrheumdis-2012-201766
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
nct01114880 at ClinicalTrials.govDocuments that mention this clinical trial
POS0918 EVALUATION OF SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING IXEKIZUMAB THERAPY OVER 2 YEARS
https://doi.org/10.1136/annrheumdis-2021-eular.1620
Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials
https://doi.org/10.1007/s40744-025-00810-5
THU0396 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS FROM THE COAST-V AND COAST-W TRIALS AT 52 WEEKS
https://doi.org/10.1136/annrheumdis-2020-eular.2053
AB0710 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH AS MEASURED BY SF-36 IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS NAIVE TO BIOLOGICAL THERAPY: 52 WEEK RESULTS OF A PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2019-eular.1612
OP0046 EFFECT OF IXEKIZUMAB TREATMENT ON MRI STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS; A POST-HOC ANALYSIS OF A PLACEBO AND ACTIVE CONTROLLED RCT
https://doi.org/10.1136/annrheumdis-2024-eular.602
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (Results)
https://doi.org/10.1136/annrheumdis-2019-216118
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
OP0238 WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND TREATED WITH IXEKIZUMAB FOR 16 WEEKS: RESULTS FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1613
FRI0398 IXEKIZUMAB IS EFFECTIVE IN THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS REGARDLESS OF THE LEVEL OF C-REACTIVE PROTEIN OR MAGNETIC RESONANCE IMAGING SCORES: 16-WEEK DATA FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1466
FRI0420 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: SF-36 RESULTS OF TWO PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.1237
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
https://doi.org/10.1136/annrheumdis-2020-219717
POS0901 IXEKIZUMAB SHOWS A DISTINCT PATTERN OF PAIN IMPROVEMENT BEYOND INFLAMMATION IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.211
Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2021-001839
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
https://doi.org/10.1136/rmdopen-2021-002165
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
https://doi.org/10.1136/annrheumdis-2023-eular.82
FRI0400 LONG-TERM SAFETY OF IXEKIZUMAB IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS/ANKYLOSING SPONDYLITIS: AN INTEGRATED ANALYSIS OF COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1232
POS0909 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS AND QUALITY OF LIFE OF ANKYLOSING SPONDYLITIS IN PATIENTS IRRESPECTIVE OF HLA-B27 STATUS: POOLED RESULTS FROM THE COAST-V AND COAST-W TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.801
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
https://doi.org/10.1007/s12325-022-02132-2
POS0931 EFFICACY AND IMPROVEMENT IN PATIENT-REPORTED OUTCOMES AT WEEKS 16 AND 52 IN IXEKIZUMAB TREATED BIOLOGICAL NAÏVE PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS ACHIEVING CLINICALLY IMPORTANT PAIN AT NIGHT REDUCTION AT WEEK 16: RESULTS FROM COAST-V TRIAL
https://doi.org/10.1136/annrheumdis-2022-eular.169
POS0908 EFFICACY OF IXEKIZUMAB THROUGH 52 WEEKS FOR IMPROVING PERIPHERAL JOINT INVOLVEMENT AMONG PATIENTS WITH RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.761
POS0957 EXTERNAL VALIDATION OF THE ALTERNATIVE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN THREE PHASE-3 RCTs
https://doi.org/10.1136/annrheumdis-2022-eular.372
POS0915 SUSTAINABILITY OF IXEKIZUMAB RESPONSE AT THE INDIVIDUAL PATIENT LEVEL OVER TIME IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1340
OP0034 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS, AND QUALITY OF LIFE IN PATIENTS WITH AXIAL SpA IRRESPECTIVE OF DISEASE DURATION: RESULTS FROM THE COAST-V, COAST-W AND COAST-X TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.164
AB0868 HOW DO EARLY DISEASE ACTIVITY AND EARLY CLINICAL RESPONSE ASSOCIATE WITH LONG-TERM OUTCOMES WITH IXEKIZUMAB IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS?
https://doi.org/10.1136/annrheumdis-2024-eular.623
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration
https://doi.org/10.1007/s12325-025-03305-5
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
FRI0421 IXEKIZUMAB SIGNIFICANTLY REDUCED PAIN, INFLAMMATION, AND FATIGUE IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLARTHRITIS (R-AXSPA)/ANKYLOSING SPONDYLITIS (AS)
https://doi.org/10.1136/annrheumdis-2019-eular.1236
Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2024-004429
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
https://doi.org/10.1136/ard-2022-222731
nct01258738 at ClinicalTrials.govDocuments that mention this clinical trial
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial
https://doi.org/10.1136/annrheumdis-2012-202533
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
nct02696798 at ClinicalTrials.govDocuments that mention this clinical trial
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis
https://doi.org/10.1136/annrheumdis-2017-212008
THU0353 Change in mri structural lesions in the sacroiliac joint after two years of etanercept therapy in comparison to a contemporary control cohort in non-radiographic axial spondyloarthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1864
THU0382 Change in sacroiliac joint structural radiographic damage after two years of etanercept therapy in comparison to a contemporary control cohort in non-radiographic axial spondyloarthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1860
FRI0216 Detection of structural lesions on t1 weighted mri versus radiography of the si joints in early axial spondyloarthritis: 2-year data
https://doi.org/10.1136/annrheumdis-2018-eular.2124
OP0107 ETANERCEPT WITHDRAWAL AND RE-TREATMENT IN PATIENTS WITH INACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AT 24 WEEKS: RESULTS OF RE-EMBARK, AN OPEN-LABEL, PHASE IV TRIAL
https://doi.org/10.1136/annrheumdis-2020-eular.1322
OP0199 Sustained remission of inflammation is associated with reduced structural damage on sacroiliac joint magnetic resonance imaging in patients with early axial spondyloarthritis: evidence to support the concept of treat-to-target
https://doi.org/10.1136/annrheumdis-2018-eular.1114
Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis
https://doi.org/10.1136/annrheumdis-2017-211605
THU0375 Characteristics associated with improvements in SPARCC SIJ and asdas scores in patients with non-radiographic axial spondyloarthritis treated with etanercept
https://doi.org/10.1136/annrheumdis-2017-eular.1873
FRI0474 Does axial spondyloarthritis phenotype correlate with imaging morphotype?
https://doi.org/10.1136/annrheumdis-2017-eular.3681
Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study
https://doi.org/10.1136/annrheumdis-2017-211313
nct02757352 at ClinicalTrials.govDocuments that mention this clinical trial
POS0926 NORMALIZATION OF HIGH SENSITIVITY CRP VERSUS CLINICAL RESPONSE TO IXEKIZUMAB AT WEEK 16 IN PATIENTS WITH RADIOGRAPHIC & NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE COAST STUDIES
https://doi.org/10.1136/annrheumdis-2021-eular.2079
POS0918 EVALUATION OF SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING IXEKIZUMAB THERAPY OVER 2 YEARS
https://doi.org/10.1136/annrheumdis-2021-eular.1620
Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials
https://doi.org/10.1007/s40744-025-00810-5
THU0396 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS FROM THE COAST-V AND COAST-W TRIALS AT 52 WEEKS
https://doi.org/10.1136/annrheumdis-2020-eular.2053
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (Results)
https://doi.org/10.1136/annrheumdis-2019-216118
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
AB1321 PSYCHOMETRIC PROPERTIES OF THE ASAS HEALTH INDEX IN PATIENTS WITH ACTIVE AS/RADIOGRAPHIC AXIAL SPA WHO HAVE PRIOR INADEQUATE RESPONSE/INTOLERANCE TO TNF INHIBITORS IN A PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2019-eular.1615
OP0238 WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND TREATED WITH IXEKIZUMAB FOR 16 WEEKS: RESULTS FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1613
FRI0398 IXEKIZUMAB IS EFFECTIVE IN THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS REGARDLESS OF THE LEVEL OF C-REACTIVE PROTEIN OR MAGNETIC RESONANCE IMAGING SCORES: 16-WEEK DATA FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1466
FRI0420 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: SF-36 RESULTS OF TWO PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.1237
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
https://doi.org/10.1136/annrheumdis-2020-219717
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
https://doi.org/10.1136/rmdopen-2021-002165
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
https://doi.org/10.1136/annrheumdis-2023-eular.82
FRI0400 LONG-TERM SAFETY OF IXEKIZUMAB IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS/ANKYLOSING SPONDYLITIS: AN INTEGRATED ANALYSIS OF COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1232
POS0909 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS AND QUALITY OF LIFE OF ANKYLOSING SPONDYLITIS IN PATIENTS IRRESPECTIVE OF HLA-B27 STATUS: POOLED RESULTS FROM THE COAST-V AND COAST-W TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.801
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
https://doi.org/10.1007/s12325-022-02132-2
POS0908 EFFICACY OF IXEKIZUMAB THROUGH 52 WEEKS FOR IMPROVING PERIPHERAL JOINT INVOLVEMENT AMONG PATIENTS WITH RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.761
POS0957 EXTERNAL VALIDATION OF THE ALTERNATIVE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN THREE PHASE-3 RCTs
https://doi.org/10.1136/annrheumdis-2022-eular.372
POS0915 SUSTAINABILITY OF IXEKIZUMAB RESPONSE AT THE INDIVIDUAL PATIENT LEVEL OVER TIME IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1340
OP0034 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS, AND QUALITY OF LIFE IN PATIENTS WITH AXIAL SpA IRRESPECTIVE OF DISEASE DURATION: RESULTS FROM THE COAST-V, COAST-W AND COAST-X TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.164
AB0471 PATIENTS WITH RADIOGRAPHIC axSpA WHO PROGRESSED FROM ASAS20 AT WEEK 16 TO ASAS40 AT WEEK 52: RESULTS FROM COAST-W
https://doi.org/10.1136/annrheumdis-2021-eular.1823
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration
https://doi.org/10.1007/s12325-025-03305-5
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
FRI0421 IXEKIZUMAB SIGNIFICANTLY REDUCED PAIN, INFLAMMATION, AND FATIGUE IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLARTHRITIS (R-AXSPA)/ANKYLOSING SPONDYLITIS (AS)
https://doi.org/10.1136/annrheumdis-2019-eular.1236
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
https://doi.org/10.1136/ard-2022-222731
nct01358175 at ClinicalTrials.govDocuments that mention this clinical trial
POS0926 NORMALIZATION OF HIGH SENSITIVITY CRP VERSUS CLINICAL RESPONSE TO IXEKIZUMAB AT WEEK 16 IN PATIENTS WITH RADIOGRAPHIC & NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE COAST STUDIES
https://doi.org/10.1136/annrheumdis-2021-eular.2079
THU0395 EFFICACY OF IXEKIZUMAB ON DISEASE ACTIVITY AND QUALITY OF LIFE IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND OBJECTIVE SIGNS OF INFLAMMATION, STRATIFIED BY BASELINE CRP/SACROILIAC JOINT MRI STATUS
https://doi.org/10.1136/annrheumdis-2020-eular.2027
THU0384 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS PATIENTS: RESULTS FROM THE COAST-X TRIAL AT 52 WEEKS
https://doi.org/10.1136/annrheumdis-2020-eular.2056
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
https://doi.org/10.1136/annrheumdis-2020-219717
Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2021-001839
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
https://doi.org/10.1136/rmdopen-2021-002165
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
https://doi.org/10.1136/annrheumdis-2023-eular.82
FRI0278 IXEKIZUMAB IMPROVES SELF-REPORTED OVERALL FUNCTIONING AND HEALTH AS MEASURED BY THE ASAS HEALTH INDEX IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS OF A PHASE 3 RANDOMIZED, ACTIVE AND PLACEBO-CONTROLLED TRIAL (COAST-X)
https://doi.org/10.1136/annrheumdis-2020-eular.1361
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
https://doi.org/10.1007/s12325-022-02132-2
POS0957 EXTERNAL VALIDATION OF THE ALTERNATIVE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN THREE PHASE-3 RCTs
https://doi.org/10.1136/annrheumdis-2022-eular.372
OP0034 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS, AND QUALITY OF LIFE IN PATIENTS WITH AXIAL SpA IRRESPECTIVE OF DISEASE DURATION: RESULTS FROM THE COAST-V, COAST-W AND COAST-X TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.164
POS0301 STRUCTURAL OUTCOMES IN THE SACROILIAC JOINT AFTER IXEKIZUMAB TREATMENT FOR 16 WEEKS IN PATIENTS WITH ACTIVE NON‑RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY GENDER, HLA-B27, AND BASELINE MRI INFLAMMATION
https://doi.org/10.1136/annrheumdis-2022-eular.2322
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration
https://doi.org/10.1007/s12325-025-03305-5
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
https://doi.org/10.1136/ard-2022-222731
nct03928704 at ClinicalTrials.govDocuments that mention this clinical trial
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
https://doi.org/10.1136/annrheumdis-2016-210023
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
https://doi.org/10.1007/s40744-020-00269-6
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
https://doi.org/10.1007/s40744-021-00380-2
SAT0315 STRUCTURAL DAMAGE PROGRESSION OVER 4 YEARS OF SECUKINUMAB TREATMENT IN ANKYLOSING SPONDYLITIS: POST-HOC ANALYSIS OF MEASURE-1 TRIAL USING A LONGITUDINAL BAYESIAN MIXTURE MODEL
https://doi.org/10.1136/annrheumdis-2019-eular.4534
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
https://doi.org/10.1136/annrheumdis-2016-209730
FRI0271 IMPACT OF HLA-B27 STATUS ON CLINICAL OUTCOMES AMONG PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.1448
SAT0259 Low rate of spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison
https://doi.org/10.1136/annrheumdis-2018-eular.1899
THU0359 Secukinumab demonstrates consistent safety over long-term exposure (up to 3 years) in patients with active ankylosing spondylitis: pooled analysis of three phase 3 trials
https://doi.org/10.1136/annrheumdis-2017-eular.4894
THU0397 SYMPTOMS OF PERIPHERAL ARTHRITIS ARE SIGNIFICANTLY IMPROVED IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2217
SAT0270 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis
https://doi.org/10.1136/annrheumdis-2018-eular.4474
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
https://doi.org/10.1136/rmdopen-2018-000749
Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate
https://doi.org/10.1136/bmjopen-2020-039059
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
https://doi.org/10.1136/rmdopen-2019-001005
nct03928743 at ClinicalTrials.govDocuments that mention this clinical trial
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2025-005969
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2025-006174
POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.833
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
https://doi.org/10.1136/ard-2022-223595
AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.2758
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2024-004202
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
https://doi.org/10.1136/ard-2023-224803
POS1107 BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.836
POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.2416
POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2292
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2020-216980
POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.1996
POS0805 SUSTAINED IMPROVEMENTS WITH BIMEKIZUMAB IN PATIENT-REPORTED SYMPTOMS OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2197
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
https://doi.org/10.1136/rmdopen-2023-004040
POS0247 RESOLUTION OF ENTHESITIS AND PERIPHERAL ARTHRITIS WITH BIMEKIZUMAB IN PATIENTS WITH AXIAL SPODYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.831
POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.1562
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2024-005026
POS0246 BIMEKIZUMAB REDUCED MRI INFLAMMATORY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.786
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
https://doi.org/10.1136/ard-2024-225933
AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.760
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.1702
POS0058 IMPACT OF BIMEKIZUMAB ON MRI INFLAMMATORY AND STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS AND POST HOC ANALYSES FROM THE BE MOBILE 1 AND 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.4903
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2025-006013
nct01786668 at ClinicalTrials.govDocuments that mention this clinical trial
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2025-005969
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2025-006174
POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.833
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
https://doi.org/10.1136/ard-2022-223595
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2024-004202
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
https://doi.org/10.1136/ard-2023-224803
POS1107 BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.836
POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2292
LBA0003 MINIMAL SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS OVER 2 YEARS OF BIMEKIZUMAB TREATMENT: RESULTS FROM A PHASE 3 OPEN-LABEL EXTENSION STUDY
https://doi.org/10.1136/annrheumdis-2024-eular.lba62
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2020-216980
POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.1996
POS0805 SUSTAINED IMPROVEMENTS WITH BIMEKIZUMAB IN PATIENT-REPORTED SYMPTOMS OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2197
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
https://doi.org/10.1136/rmdopen-2023-004040
POS0247 RESOLUTION OF ENTHESITIS AND PERIPHERAL ARTHRITIS WITH BIMEKIZUMAB IN PATIENTS WITH AXIAL SPODYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.831
POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.1562
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2024-005026
OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.2441
POS0246 BIMEKIZUMAB REDUCED MRI INFLAMMATORY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.786
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
https://doi.org/10.1136/ard-2024-225933
AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.760
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.1702
Axial spondyloarthritis: new advances in diagnosis and management
https://doi.org/10.1136/bmj.m4447
POS0058 IMPACT OF BIMEKIZUMAB ON MRI INFLAMMATORY AND STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS AND POST HOC ANALYSES FROM THE BE MOBILE 1 AND 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.4903
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2025-006013
nct03502616 at ClinicalTrials.govDocuments that mention this clinical trial
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
AB0750 Back pain and morning stiffness as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
https://doi.org/10.1136/annrheumdis-2022-eular.28
OP0239 PSYCHOMETRIC EVALUATION OF FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS
https://doi.org/10.1136/annrheumdis-2021-eular.62
POS0296 INTEGRATED SAFETY ANALYSIS OF TOFACITINIB IN ANKYLOSING SPONDYLITIS CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.2076
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2019-001042
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
https://doi.org/10.1136/annrheumdis-2020-219601
Old and new treatment targets in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2015-000054
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2016-210322
THU0352 Tofacitinib treatment is associated with attainment of the minimally important reduction in axial mri inflammation in patients with ankylosing spondylitis
https://doi.org/10.1136/annrheumdis-2017-eular.2447
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial
https://doi.org/10.1136/rmdopen-2022-002253
SAT0221 Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/annrheumdis-2018-eular.3247
Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial
https://doi.org/10.1007/s40744-023-00564-y
AB0937 TOFACITINIB EFFICACY AND SAFETY IN PATIENTS WITH ANKYLOSING SPONDYLITIS BY BASELINE C‑REACTIVE PROTEIN LEVELS: A POST HOC ANALYSIS
https://doi.org/10.1136/annrheumdis-2023-eular.2118
nct03928704 at ClinicalTrials.govDocuments that mention this clinical trial
POS1116 TIME TO IMPROVEMENT OF PAIN, MORNING STIFFNESS AND DISEASE ACTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH TOFACITINIB
https://doi.org/10.1136/annrheumdis-2023-eular.2417
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
AB0750 Back pain and morning stiffness as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
https://doi.org/10.1136/annrheumdis-2022-eular.28
OP0239 PSYCHOMETRIC EVALUATION OF FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS
https://doi.org/10.1136/annrheumdis-2021-eular.62
POS0296 INTEGRATED SAFETY ANALYSIS OF TOFACITINIB IN ANKYLOSING SPONDYLITIS CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.2076
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
https://doi.org/10.1136/annrheumdis-2020-219601
POS0305 TIME TO IMPROVEMENT OF FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN A STUDY OF TOFACITINIB
https://doi.org/10.1136/annrheumdis-2022-eular.2391
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
https://doi.org/10.1136/ard-2023-223850
Improvement of Fatigue in Patients with Ankylosing Spondylitis Receiving Tofacitinib: Analyses of a Phase 3 Randomized Controlled Trial
https://doi.org/10.1007/s40744-024-00727-5
POS0895 EFFECT OF TOFACITINIB ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.106
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial
https://doi.org/10.1136/rmdopen-2022-002253
AB0937 TOFACITINIB EFFICACY AND SAFETY IN PATIENTS WITH ANKYLOSING SPONDYLITIS BY BASELINE C‑REACTIVE PROTEIN LEVELS: A POST HOC ANALYSIS
https://doi.org/10.1136/annrheumdis-2023-eular.2118
nct03895203 at ClinicalTrials.govDocuments that mention this clinical trial
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2025-005969
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2025-006174
POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.833
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
https://doi.org/10.1136/ard-2022-223595
AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.2758
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2024-004202
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
https://doi.org/10.1136/ard-2023-224803
POS1107 BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.836
POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.2416
POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2292
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2020-216980
POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.1996
POS0805 SUSTAINED IMPROVEMENTS WITH BIMEKIZUMAB IN PATIENT-REPORTED SYMPTOMS OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2197
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
https://doi.org/10.1136/rmdopen-2023-004040
POS0247 RESOLUTION OF ENTHESITIS AND PERIPHERAL ARTHRITIS WITH BIMEKIZUMAB IN PATIENTS WITH AXIAL SPODYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.831
POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.1562
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2024-005026
POS0246 BIMEKIZUMAB REDUCED MRI INFLAMMATORY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.786
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
https://doi.org/10.1136/ard-2024-225933
AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.760
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.1702
POS0058 IMPACT OF BIMEKIZUMAB ON MRI INFLAMMATORY AND STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS AND POST HOC ANALYSES FROM THE BE MOBILE 1 AND 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.4903
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2025-006013
Documents that mention this clinical trial
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2025-006174
POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL
https://doi.org/10.1136/annrheumdis-2023-eular.1694
Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year
https://doi.org/10.1007/s13555-025-01599-5
AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.2758
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
https://doi.org/10.1136/ard-2023-224431
AB1100 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL DISEASE CONTROL CRITERIA WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION, PAIN AND FATIGUE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM BE OPTIMAL, A PHASE 3 RANDOMISED, PLACEBO-CONTROLLED STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.1703
POS0969 BIMEKIZUMAB-TREATED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SHOWED SUSTAINED ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND REMISSION: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2557
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00652-7
Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003548
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2024-005026
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes
https://doi.org/10.1136/rmdopen-2021-002074
POS1534 BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM BE OPTIMAL, A PHASE 3, ACTIVE-REFERENCE STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.1667
POS0590-HPR IDENTIFICATION OF RESPONDER AND DISEASE ACTIVITY THRESHOLDS FOR THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) QUESTIONNAIRE USING POOLED DATA FROM TWO PHASE 3 TRIALS OF BIMEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.1980
POS1533 BIMEKIZUMAB TREATMENT RESULTED IN CLINICALLY MEANINGFUL IMPROVEMENTS IN THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) SCORES USING POOLED RESULTS FROM TWO PHASE 3 TRIALS IN PATIENTS WITH PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.1305
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00706-w
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2024-004464
LB0001 BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.5016
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
https://doi.org/10.1007/s40744-024-00708-8
POS0961 BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.1239
-
Funding
Funding for this research was provided by:
UCB Pharma
- License Information
